Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AN
MCID: ACN002
MIFTS: 60

Acanthosis Nigricans (AN)

Categories: Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Acanthosis Nigricans

About this section

MalaCards integrated aliases for Acanthosis Nigricans:

Name: Acanthosis Nigricans 57 12 76 53 29 55 6 44 15 73
an - Acanthosis Nigricans 12
Keratosis Nigricans 12
an 53

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
acanthosis nigricans:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 100600
Disease Ontology 12 DOID:3138
ICD10 33 L83
MeSH 44 D000052
NCIt 50 C26687
SNOMED-CT 68 402599005 72129000
MedGen 42 C0000889
SNOMED-CT via HPO 69 263681008
UMLS 73 C0000889
Sources

Summaries for Acanthosis Nigricans

About this section
NIH Rare Diseases : 53 Acanthosis nigricans (AN) is a skin disorder in which there is darker, thick, velvety skin in body folds and creases. This condition usually appears slowly and doesn't cause any symptoms other than skin changes. Eventually, dark, velvety skin with very visible markings and creases appears in the armpits, groin and neck folds, and over the joints of the fingers and toes. Less commonly, the lips, palms, soles of the feet, or other areas may be affected. The exact cause of this condition is not well understood; but it can be inherited or related to medical problems such as obesity, diabetes mellitus (insulin- resistance), some prescription drugs, and cancer.

MalaCards based summary : Acanthosis Nigricans, also known as an - acanthosis nigricans, is related to beare-stevenson cutis gyrata syndrome and pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities, and has symptoms including pruritus An important gene associated with Acanthosis Nigricans is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Metformin and Hypoglycemic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and lung, and related phenotypes are acanthosis nigricans and Decreased viability

Wikipedia : 76 Acanthosis nigricans is a brown to black, poorly defined, velvety hyperpigmentation of the skin. It is... more...

Description from OMIM: 100600
Sources

Related Diseases for Acanthosis Nigricans

About this section

Diseases related to Acanthosis Nigricans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 beare-stevenson cutis gyrata syndrome 33.8 FGFR2 FGFR3
2 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 32.3 IGF1 INS INSR
3 alstrom syndrome 32.1 ALMS1 INS LEP
4 lipodystrophy, familial partial, type 2 31.7 INS LEP LMNA
5 congenital generalized lipodystrophy 31.6 INS LEP LMNA
6 luteoma 30.8 FGFR2 FGFR3
7 nonalcoholic steatohepatitis 30.3 ADIPOQ INS LEP
8 acromegaly 30.0 IGF1 INS PRL
9 morbid obesity 29.8 ADIPOQ INS LEP PPARG
10 amenorrhea 29.4 LEP PRL SHBG
11 hyperandrogenism 29.0 IGF1 INS INSR PRL SHBG
12 gestational diabetes 28.7 ADIPOQ INS INSR LEP SHBG
13 hypothyroidism 28.6 IGF1 LEP PRL SHBG
14 ovarian disease 28.3 IGF1 INS PRL SHBG
15 hyperinsulinism 28.2 IGF1 INS INSR LEP SHBG
16 polycystic ovary syndrome 28.2 IGF1 INS INSR LEP PRL SHBG
17 diabetes mellitus 27.3 ADIPOQ ALMS1 IGF1 INS INSR LEP
18 diabetes mellitus, noninsulin-dependent 25.9 ADIPOQ IGF1 IGF1R INS INSR LEP
19 crouzon syndrome with acanthosis nigricans 12.7
20 achondroplasia, severe, with developmental delay and acanthosis nigricans 12.7
21 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.5
22 acanthosis nigricans with muscle cramps and acral enlargement 12.4
23 insulin-resistant acanthosis nigricans, type a 12.3
24 cutis gyratum acanthosis nigricans craniosynostosis 12.1
25 leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome 12.1
26 hair-an syndrome 12.1
27 lelis syndrome 12.1
28 retinitis pigmentosa, deafness, mental retardation, and hypogonadism 11.2
29 papillomatosis, confluent and reticulated 11.1
30 ectodermal dysplasia with natal teeth, turnpenny type 11.1
31 lipodystrophy, congenital generalized, type 1 11.1
32 aromatase deficiency 11.1
33 insulin-resistance type b 11.1
34 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 11.1
35 insulin autoimmune syndrome 10.8 INS INSR
36 hemifacial hyperplasia 10.8 FGFR2 FGFR3
37 plagiocephaly 10.7 FGFR2 FGFR3
38 osteoglophonic dysplasia 10.7 FGFR2 FGFR3
39 adenocarcinoma 10.6
40 acquired generalized lipodystrophy 10.5 ADIPOQ LEP
41 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.5 INS LEP
42 obesity-hypoventilation syndrome 10.5 ADIPOQ LEP
43 crouzon syndrome 10.5
44 idiopathic recurrent pericarditis 10.5 ADIPOQ LEP
45 gastric adenocarcinoma 10.4
46 secondary adrenal insufficiency 10.4 IGF1 INS
47 idiopathic edema 10.4 ADIPOQ INS PPARG
48 jackson-weiss syndrome 10.4 FGFR2 FGFR3
49 achondroplasia 10.3
50 pituitary apoplexy 10.3 INS PRL

Graphical network of the top 20 diseases related to Acanthosis Nigricans:



Diseases related to Acanthosis Nigricans
Sources

Symptoms & Phenotypes for Acanthosis Nigricans

About this section

Symptoms via clinical synopsis from OMIM:

57
Skin:
benign acanthosis nigricans
thick hyperpigmented flexural area skin


Clinical features from OMIM:

100600

Human phenotypes related to Acanthosis Nigricans:

32
# Description HPO Frequency HPO Source Accession
1 acanthosis nigricans 32 HP:0000956

UMLS symptoms related to Acanthosis Nigricans:


pruritus

GenomeRNAi Phenotypes related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.62 IGF1R INSR PPARG FGFR3
2 Decreased viability GR00221-A-2 9.62 IGF1R INSR PPARG FGFR3
3 Decreased viability GR00221-A-3 9.62 FGFR3 IGF1R INSR PPARG
4 Decreased viability GR00221-A-4 9.62 INSR PPARG
5 Decreased viability GR00301-A 9.62 IGF1R
6 Decreased viability GR00342-S-2 9.62 IGF1R
7 Decreased viability GR00402-S-2 9.62 IGF1R INSR PPARG FGFR3
8 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.46 FGFR3 IGF1R INSR FGFR2
9 Decreased substrate adherent cell growth GR00193-A-2 9.35 FGFR2
10 Decreased substrate adherent cell growth GR00193-A-3 9.35 FGFR3 INSR FGFR2
11 Decreased substrate adherent cell growth GR00193-A-4 9.35 INSR

MGI Mouse Phenotypes related to Acanthosis Nigricans:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 ADIPOQ FGFR2 ALMS1 INSR INS LEP
2 endocrine/exocrine gland MP:0005379 10.35 ALMS1 ADIPOQ FGFR2 INS LEP INSR
3 growth/size/body region MP:0005378 10.35 ADIPOQ FGFR2 ALMS1 INSR INS LEP
4 homeostasis/metabolism MP:0005376 10.35 ADIPOQ FGFR2 ALMS1 INS LEP INSR
5 immune system MP:0005387 10.34 ALMS1 FGFR3 ADIPOQ FGFR2 INS LEP
6 cellular MP:0005384 10.33 ADIPOQ FGFR2 ALMS1 INSR INS LEP
7 adipose tissue MP:0005375 10.31 ALMS1 ADIPOQ FGFR2 INS LEP INSR
8 cardiovascular system MP:0005385 10.3 ADIPOQ FGFR2 INSR INS LEP PRMT7
9 hematopoietic system MP:0005397 10.29 ADIPOQ FGFR2 INSR INS LEP PRMT7
10 liver/biliary system MP:0005370 10.22 ALMS1 ADIPOQ FGFR2 LEP INSR LMNA
11 integument MP:0010771 10.21 ADIPOQ FGFR2 INS LEP PPARG LMNA
12 mortality/aging MP:0010768 10.16 ADIPOQ FGFR2 INSR INS LEP PPARG
13 nervous system MP:0003631 10.15 FGFR2 ALMS1 INS LEP INSR PRMT7
14 digestive/alimentary MP:0005381 10.13 FGFR2 INSR INS LEP LMNA IGF1R
15 hearing/vestibular/ear MP:0005377 10.1 FGFR2 ALMS1 PPARG LMNA IGF1R IGF1
16 muscle MP:0005369 10.09 ADIPOQ FGFR2 INS LEP INSR PPARG
17 neoplasm MP:0002006 10.06 FGFR2 FGFR3 ADIPOQ LEP PPARG PRL
18 renal/urinary system MP:0005367 10.02 ALMS1 FGFR3 ADIPOQ FGFR2 INS LEP
19 reproductive system MP:0005389 10 FGFR2 ALMS1 INS LEP INSR PPARG
20 limbs/digits/tail MP:0005371 9.97 FGFR2 LEP LMNA IGF1R IGF1 FGFR3
21 respiratory system MP:0005388 9.76 ADIPOQ FGFR2 INSR LEP LMNA IGF1R
22 skeleton MP:0005390 9.65 ADIPOQ FGFR2 INS LEP PRMT7 PPARG
23 vision/eye MP:0005391 9.17 FGFR2 ALMS1 INS LEP PPARG LMNA
Sources

Drugs & Therapeutics for Acanthosis Nigricans

About this section

Drugs for Acanthosis Nigricans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
2 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
3
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
4
Enclomiphene Investigational Phase 3,Phase 2 15690-57-0
5 Autoantibodies Phase 3
6 insulin Phase 3,Phase 2
7 Insulin, Globin Zinc Phase 3,Phase 2
8 Clomiphene Phase 3,Phase 2
9 Estrogen Antagonists Phase 3,Phase 2
10 Estrogen Receptor Modulators Phase 3,Phase 2
11 Estrogens Phase 3,Phase 2
12 Fertility Agents Phase 3,Phase 2
13 Hormone Antagonists Phase 3,Phase 2
14 Hormones Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
16 Selective Estrogen Receptor Modulators Phase 3,Phase 2
17 Zuclomiphene Phase 3,Phase 2
18 Aromatase Inhibitors Phase 3
19 Steroid Synthesis Inhibitors Phase 3
20
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
21
Spironolactone Approved Phase 2 1952-01-7, 52-01-7 5833
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
23 Antineoplastic Agents, Hormonal Phase 2
24 diuretics Phase 2
25 Diuretics, Potassium Sparing Phase 2
26 Mineralocorticoid Receptor Antagonists Phase 2
27 Mineralocorticoids Phase 2
28 Natriuretic Agents Phase 2
29 Citrate Nutraceutical Phase 2
30
Melatonin Approved, Nutraceutical, Vet_approved Not Applicable 73-31-4 896
31
Pyridoxal Approved, Nutraceutical Not Applicable 66-72-8 1050
32
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Not Applicable 65-23-6 1054
33 Antioxidants Not Applicable
34 Calcium, Dietary Not Applicable
35 Central Nervous System Depressants Not Applicable
36 Protective Agents Not Applicable
37 Vitamin B 6 Not Applicable
38 Vitamin B Complex Not Applicable
39 Vitamins Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
2 Adjunctive Metformin Therapy in Double Diabetes Completed NCT01334125 Phase 3 Metformin;Placebo
3 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
4 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
5 Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients Completed NCT02562664 Phase 2 CC;Placebo tablets;Metformin
6 Prevalence of Carbohydrate Intolerance in Lean and Obese Children Unknown status NCT00000112
7 The Efficacy of an Inpatient Program for Long-term Weight Maintenance in Children and Adolescents With Morbid Obesity Unknown status NCT01254266 Not Applicable
8 Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia Completed NCT01125150 Metformin
9 Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism Completed NCT02604095 Not Applicable

Search NIH Clinical Center for Acanthosis Nigricans

Cochrane evidence based reviews: acanthosis nigricans

Sources

Genetic Tests for Acanthosis Nigricans

About this section

Genetic tests related to Acanthosis Nigricans:

# Genetic test Affiliating Genes
1 Acanthosis Nigricans 29
Sources

Anatomical Context for Acanthosis Nigricans

About this section

MalaCards organs/tissues related to Acanthosis Nigricans:

41
Skin, Ovary, Lung, Prostate, Liver, Thyroid, Testes
Sources

Publications for Acanthosis Nigricans

About this section

Articles related to Acanthosis Nigricans:

(show top 50) (show all 613)
# Title Authors Year
1
Velvety Hyperpigmentation on Hands and Feet of a Young Girl: Acral Acanthosis Nigricans. ( 29865956 )
2018
2
Comparative study using fractional carbon dioxide laser versus glycolic acid peel in treatment of pseudo-acanthosis nigricans. ( 29713841 )
2018
3
Familial acanthosis nigricans with p.K650T FGFR3 mutation. ( 29068064 )
2018
4
Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans. ( 29706998 )
2018
5
Acanthosis nigricans and the metabolic syndrome. ( 29241752 )
2018
6
Crouzon with Acanthosis Nigricans and Odontogenic Tumors: A Rare Form of Syndromic Craniosynostosis. ( 29351036 )
2018
7
Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. ( 29178944 )
2017
8
The Associations of Serum Uric Acid with Obesity-Related Acanthosis nigricans and Related Metabolic Indices. ( 28367214 )
2017
9
Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges. ( 28031729 )
2017
10
Paediatric obesity treatment had better outcomes when children were younger, well motivated and did not have acanthosis nigricans. ( 28685930 )
2017
11
Concomitant confluent and reticulated papillomatosis and acanthosis nigricans in an obese girl with insulin resistance successfully treated with oral minocycline: Case report and published work review. ( 28295566 )
2017
12
Image Gallery: Generalized mucosal and cutaneous papillomatosis, a unique sign of malignant acanthosis nigricans. ( 28504375 )
2017
13
The Clinical Characteristics of Obese Patients with Acanthosis Nigricans and Its Independent Risk Factors. ( 28081576 )
2017
14
Association of metabolic syndrome with low birth weight, intake of high-calorie diets and acanthosis nigricans in children and adolescents with overweight and obesity. ( 28440765 )
2017
15
A study of the association of acanthosis nigricans with subclinical atherosclerosis. ( 28164885 )
2017
16
Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation. ( 28181399 )
2017
17
A Mutation in INSR in a Child Presenting with Severe Acanthosis Nigricans. ( 28663160 )
2017
18
Laparoscopic sleeve gastrectomy improves body composition and alleviates insulin resistance in obesity related acanthosis nigricans. ( 29115953 )
2017
19
Acanthosis Nigricans ( 28613711 )
2017
20
Comment about the article: A<Association of metabolic syndrome with low birth weight, intake of high-calorie diets and acanthosis nigricans in children and adolescents with overweight and obesityA>. ( 29066311 )
2017
21
Effects of glycolic acid peeling on the cutaneous manifestation of generalized acanthosis nigricans caused by FGFR3 mutation: A report of one sporadic and two familial cases. ( 28620983 )
2017
22
Reply to the comment to our article titled: A<Association of metabolic syndrome with low birth weight of birth, intake hypercaloric diets and acanthosis nigricans in childhood and teens with overweight and obesityA>. ( 29179858 )
2017
23
Acanthosis nigricans: A screening test for insulin resistance - An important risk factor for diabetes mellitus type-2. ( 29026747 )
2017
24
Acanthosis Nigricans and Its Response to Metformin. ( 28758315 )
2017
25
Successful Repigmentation of Vitiligo-Like Hypopigmentation in a Case of Acanthosis Nigricans. ( 28392666 )
2017
26
Facial Acanthosis Nigricans: A Morphological Marker of Metabolic Syndrome. ( 29263532 )
2017
27
Prevalence of Acanthosis nigricans and Related Factors in Iranian Obese Children. ( 28892990 )
2017
28
Severe, Malignant Acanthosis Nigricans Associated with Adenocarcinoma of the Endometrium in a Young Obese Female. ( 28413386 )
2017
29
Arterial stiffening, insulin resistance and acanthosis nigricans in a community sample of adolescents with obesity. ( 28465605 )
2017
30
Acanthosis nigricans in a Japanese boy with hypochondroplasia due to a K650T mutation in<i>FGFR3</i>. ( 29026271 )
2017
31
Terra Firma-Forme Dermatosis Misdiagnosed as Nevoid Acanthosis Nigricans. ( 28930108 )
2017
32
Gastric Cancer Associated With Malignant Acanthosis Nigricans. ( 28317636 )
2017
33
Prevalence of obesity and acanthosis nigricans among young children in the children's healthy living program in the United States Affiliated Pacific. ( 27631218 )
2016
34
IMAGES IN CLINICAL MEDICINE. Acanthosis Nigricans and Insulin Resistance. ( 27305209 )
2016
35
Bilaterally mammary acanthosis nigricans as paraneoplastic manifestation of prostate adenocarcinoma. ( 27595210 )
2016
36
A descriptive study of facial acanthosis nigricans and its association with body mass index, waist circumference and insulin resistance using HOMA2 IR. ( 27990384 )
2016
37
A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans. ( 27746646 )
2016
38
Serum Irisin Level is Higher and Related with Insulin in Acanthosis Nigricans-related Obesity. ( 26588491 )
2016
39
ACANTHOSIS NIGRICANS AND SEVERE INSULIN RESISTANCE IN A BOY WITH ATAXIA. ( 27124696 )
2016
40
Acanthosis Nigricans associated with clear-cell renal cell carcinoma. ( 27284539 )
2016
41
Diffuse esophageal papillomatosis in a patient with acanthosis nigricans. ( 27167874 )
2016
42
Hyperpigmented Plaques of the Alar Crease: An Unusual Presentation of Acanthosis Nigricans. ( 26860419 )
2016
43
Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. ( 27999648 )
2016
44
Lelis Syndrome: A Rare Cause of Acanthosis Nigricans. ( 27595879 )
2016
45
Assessment of EGF receptor ligand expression in gastric carcinoma and in lesional skin of paraneoplastic acanthosis nigricans: a case report. ( 27987313 )
2016
46
Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation. ( 26818779 )
2016
47
Linear acanthosis nigricans on the anterior neck: Koebner phenomenon observed in a patient with acanthosis nigricans. ( 27569660 )
2016
48
Unilateral nevoid acanthosis nigricans treated with CO2 laser. ( 27457822 )
2016
49
Acanthosis Nigricans as a Clinical Predictor of Insulin Resistance in Obese Children. ( 28090470 )
2016
50
Acanthosis nigricans in insulinoma: before and after successful surgical enucleation. ( 27836838 )
2016
Sources

Variations for Acanthosis Nigricans

About this section

ClinVar genetic disease variations for Acanthosis Nigricans:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
2 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh38 Chromosome 4, 1806162: 1806162
3 46;Y;inv(X)(q27q28) inversion Uncertain significance
4 FGFR3 NM_000142.4(FGFR3): c.1943A> C (p.Tyr648Ser) single nucleotide variant Likely pathogenic rs587779383 GRCh37 Chromosome 4, 1807884: 1807884
5 FGFR3 NM_000142.4(FGFR3): c.1943A> C (p.Tyr648Ser) single nucleotide variant Likely pathogenic rs587779383 GRCh38 Chromosome 4, 1806157: 1806157
6 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh37 Chromosome 16, 68363008: 68363008
7 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh38 Chromosome 16, 68329105: 68329105
8 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 16, 68389688: 68389688
9 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 16, 68355785: 68355785
Sources

Expression for Acanthosis Nigricans

About this section
Search GEO for disease gene expression data for Acanthosis Nigricans.
Sources

Pathways for Acanthosis Nigricans

About this section

Pathways related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 64
Show member pathways
 13.55 FGFR2 FGFR3 IGF1R INS INSR LEP
2
TGF-Beta Pathway 64
Show member pathways
 13.39 FGFR2 FGFR3 IGF1 IGF1R INS INSR
3
p70S6K Signaling 64
Show member pathways
 12.96 FGFR2 FGFR3 IGF1 IGF1R INS INSR
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.83 FGFR2 FGFR3 IGF1 IGF1R INS INSR
5
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.77 FGFR2 FGFR3 IGF1 IGF1R INSR
6
Endometrial cancer 37
Show member pathways
 12.77 FGFR2 IGF1 IGF1R INS PPARG
7
Pathways in cancer 37
12.74 FGFR2 FGFR3 IGF1 IGF1R PPARG
8
MAPK signaling pathway 1 37
12.67 FGFR2 FGFR3 IGF1 IGF1R INS INSR
9
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.6 FGFR2 FGFR3 INS INSR
10
Ras signaling pathway 37
Show member pathways
 12.6 FGFR2 FGFR3 IGF1 IGF1R INS INSR
11
Glucose / Energy Metabolism 4
12.45 ADIPOQ IGF1R INS INSR PPARG
12
Apoptosis Pathway 72
Show member pathways
 12.36 FGFR2 FGFR3 IGF1R INSR
13
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.26 FGFR2 FGFR3 IGF1 IGF1R INS INSR
14
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.23 IGF1 IGF1R INSR PPARG
15
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.09 IGF1 IGF1R LMNA
16
Tyrosine Kinases / Adaptors 4
12.06 FGFR2 FGFR3 IGF1R INSR
17
AKT Signaling Pathway 67
12.06 FGFR2 FGFR3 IGF1R INSR LMNA
18
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.04 FGFR2 IGF1 IGF1R
19
Signaling pathways regulating pluripotency of stem cells 37
12.02 FGFR2 FGFR3 IGF1 IGF1R
20
FoxO signaling pathway 37
Show member pathways
 12.01 IGF1 IGF1R INS INSR
21
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.98 FGFR2 FGFR3 IGF1R INSR
22
Hepatic ABC Transporters 64
Show member pathways
 11.92 IGF1R INS INSR
23
Senescence and Autophagy in Cancer 1
11.85 IGF1 IGF1R INS
24
HIF-1 signaling pathway 37
11.84 IGF1 IGF1R INS INSR
25
Longevity regulating pathway 37
Show member pathways
 11.81 ADIPOQ IGF1 IGF1R INS INSR PPARG
26
Type II diabetes mellitus 37 1
Show member pathways
 11.8 ADIPOQ INS INSR
27
Endochondral Ossification 1
11.61 FGFR3 IGF1 IGF1R
28
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 11.58 ADIPOQ IGF1 IGF1R INS INSR LEP
29
Adipogenesis 1
11.55 ADIPOQ IGF1 INS LEP LMNA PPARG
30
Signaling events mediated by PTP1B 1
11.43 INS INSR LEP PRL
31
Ovarian steroidogenesis 37
11.4 IGF1 IGF1R INS INSR
32
Aldosterone-regulated sodium reabsorption 37
11.34 IGF1 INS INSR
33
Alzheimers Disease Pathway 64
11.32 FGFR2 FGFR3 IGF1R INSR
34
Differentiation of white and brown adipocyte 1
11.12 ADIPOQ LEP PPARG
35
Transcription factor regulation in adipogenesis 1
10.9 ADIPOQ INSR LEP PPARG
Sources

GO Terms for Acanthosis Nigricans

About this section

Cellular components related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 ADIPOQ FGFR2 FGFR3 IGF1 INS LEP
2 endosome lumen GO:0031904 9.26 INS PRL
3 receptor complex GO:0043235 9.26 FGFR2 FGFR3 IGF1R INSR
4 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.62 IGF1 IGF1R

Biological processes related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.98 ADIPOQ IGF1 INS LEP PRL
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 FGFR2 FGFR3 IGF1R INSR
3 negative regulation of apoptotic process GO:0043066 9.95 FGFR2 FGFR3 IGF1 IGF1R INS INSR
4 positive regulation of cell migration GO:0030335 9.91 IGF1 IGF1R INS INSR
5 activation of MAPK activity GO:0000187 9.89 IGF1 INS INSR
6 response to ethanol GO:0045471 9.88 ADIPOQ FGFR2 LEP
7 protein autophosphorylation GO:0046777 9.88 FGFR2 FGFR3 IGF1R INSR
8 response to organic substance GO:0010033 9.87 IGF1 INS PPARG
9 peptidyl-tyrosine phosphorylation GO:0018108 9.87 FGFR2 FGFR3 IGF1R INSR
10 cellular response to insulin stimulus GO:0032869 9.86 ADIPOQ INSR PPARG
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 ADIPOQ IGF1 INS
12 insulin receptor signaling pathway GO:0008286 9.85 IGF1R INS INSR
13 response to nutrient GO:0007584 9.85 ADIPOQ LEP PPARG
14 response to glucose GO:0009749 9.85 ADIPOQ IGF1 INS
15 negative regulation of signal transduction GO:0009968 9.85 FGFR2 FGFR3 IGF1R INSR
16 response to insulin GO:0032868 9.84 IGF1 INS LEP
17 cellular response to retinoic acid GO:0071300 9.83 FGFR2 LEP PPARG
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 IGF1 INS LEP
19 positive regulation of protein kinase B signaling GO:0051897 9.83 FGFR2 FGFR3 INS INSR LEP
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 FGFR3 IGF1 LEP
21 glucose metabolic process GO:0006006 9.81 ADIPOQ INS LEP
22 positive regulation of kinase activity GO:0033674 9.76 FGFR2 FGFR3 IGF1R INSR
23 positive regulation of cell proliferation GO:0008284 9.76 FGFR2 FGFR3 IGF1 IGF1R INS INSR
24 activation of protein kinase B activity GO:0032148 9.73 IGF1 INS INSR
25 positive regulation of JAK-STAT cascade GO:0046427 9.72 LEP PRL
26 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.71 IGF1 LMNA
27 positive regulation of cellular protein metabolic process GO:0032270 9.71 ADIPOQ INS
28 regulation of fat cell differentiation GO:0045598 9.71 LEP PPARG
29 regulation of multicellular organism growth GO:0040014 9.71 FGFR2 IGF1 PRL
30 fatty acid oxidation GO:0019395 9.7 ADIPOQ PPARG
31 insulin-like growth factor receptor signaling pathway GO:0048009 9.7 IGF1 IGF1R
32 negative regulation of gluconeogenesis GO:0045721 9.7 ADIPOQ INS
33 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.7 ADIPOQ PPARG
34 positive regulation of mitotic nuclear division GO:0045840 9.7 IGF1 INS INSR
35 amyloid-beta clearance GO:0097242 9.69 IGF1R INSR
36 positive regulation of glycolytic process GO:0045821 9.69 IGF1 INS INSR
37 dendritic spine maintenance GO:0097062 9.68 IGF1R INSR
38 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 IGF1 INS LEP
39 positive regulation of DNA replication GO:0045740 9.67 IGF1 IGF1R INS INSR
40 positive regulation of phospholipase activity GO:0010518 9.66 FGFR2 FGFR3
41 endochondral bone growth GO:0003416 9.65 FGFR2 FGFR3
42 positive regulation of glycogen biosynthetic process GO:0045725 9.65 IGF1 INS INSR
43 response to nutrient levels GO:0031667 9.65 ADIPOQ IGF1 INS LEP PRL
44 negative regulation of acute inflammatory response GO:0002674 9.64 INS PPARG
45 positive regulation of respiratory burst GO:0060267 9.63 INS INSR
46 neuron projection maintenance GO:1990535 9.62 INS INSR
47 regulation of protein localization to nucleus GO:1900180 9.62 LEP LMNA
48 positive regulation of glucose import GO:0046326 9.62 ADIPOQ IGF1 INS INSR
49 positive regulation of protein complex disassembly GO:0043243 9.61 IGF1R INSR
50 bone mineralization involved in bone maturation GO:0035630 9.6 IGF1 LEP

Molecular functions related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.83 FGFR2 FGFR3 IGF1R INSR
2 protein tyrosine kinase activity GO:0004713 9.71 FGFR2 FGFR3 IGF1R INSR
3 fibroblast growth factor binding GO:0017134 9.56 FGFR2 FGFR3
4 MAP kinase kinase kinase activity GO:0004709 9.56 FGFR2 FGFR3 IGF1R INSR
5 alpha-actinin binding GO:0051393 9.55 ALMS1 PPARG
6 phosphatidylinositol 3-kinase binding GO:0043548 9.54 IGF1R INSR
7 insulin receptor binding GO:0005158 9.54 IGF1 IGF1R INS
8 insulin-like growth factor I binding GO:0031994 9.51 IGF1R INSR
9 insulin-like growth factor receptor binding GO:0005159 9.5 IGF1 INS INSR
10 insulin receptor substrate binding GO:0043560 9.49 IGF1R INSR
11 receptor activator activity GO:0030546 9.48 IGF1 INS
12 insulin binding GO:0043559 9.46 IGF1R INSR
13 mitogen-activated protein kinase kinase binding GO:0031434 9.46 FGFR2 FGFR3 IGF1R INSR
14 fibroblast growth factor-activated receptor activity GO:0005007 9.43 FGFR2 FGFR3
15 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 FGFR2 FGFR3 IGF1R INSR
16 hormone activity GO:0005179 9.02 ADIPOQ IGF1 INS LEP PRL
Sources

Sources for Acanthosis Nigricans

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....